Related Experiment Video
Updated: Jan 11, 2026

The Goeckerman Regimen for the Treatment of Moderate to Severe Psoriasis
Published on: July 11, 2013
Clinical Features and Long-Term Outcomes in 109 Pediatric Generalized Pustular Psoriasis
Jiaying Li1,2, Zhaoyang Wang1,2, Chaoyang Miao1,2
1Department of Dermatology, Beijing Children's Hospital, Capital Medical University, National Center for Children's Health, Beijing, China.
Insights
Pediatric-onset generalized pustular psoriasis (PGPP) flares decrease with age but remain common. Earlier onset PGPP is linked to more frequent flares, with biologics now the primary treatment.
Area of Science:
- Dermatology
- Pediatric Immunology
- Clinical Research
Background:
- Pediatric-onset generalized pustular psoriasis (PGPP) is a rare, challenging inflammatory condition.
- Characterized by recurrent flares and complex management needs.
Purpose of the Study:
- To review clinical features of PGPP.
- To analyze flare patterns and identify triggers.
- To evaluate current and evolving treatment options.
Main Methods:
- Retrospective analysis of 109 PGPP patients (2006-2023).
- Data collection via medical records and telephone surveys.
- Analysis of flare frequency, duration, triggers, and treatment modalities.
Main Results:
- Median onset age was 6 years; higher prevalence in males.
- Respiratory infection was the most common trigger.
- Flare frequency and duration decreased with age; earlier onset correlated with higher frequency.
- Conventional therapies (acitretin) were common before 2020; biologics (secukinumab) are now prevalent.
Conclusions:
- PGPP flares tend to decrease with age, but recurrence is frequent.
- Early onset PGPP may be associated with increased flare frequency.
- Biologic agents represent the current standard of care for PGPP.
Introduction:
Pediatric-onset generalized pustular psoriasis (PGPP) is a rare inflammatory disorder characterized by recurrent flares and challenging management. This study aimed to review the clinical features, flare patterns, and treatment options.
Methods:
We analyzed PGPP patients diagnosed at Beijing Children's Hospital from 2006 to 2023 who had complete medical record. Data on clinical characteristics, flare numbers, and flare duration were collected through medical record and telephone survey. The flare frequency was calculated by dividing the flare numbers by the years in each age range. Flare duration was categorized as ≤4 weeks or >4 weeks. In addition, we investigated the factors associated with flare frequency in PGPP patients.
Results:
A total of 109 patients with PGPP were included in the study, with a follow-up duration ranging from 1.90 to 22.80 years. The median age of onset was 6.00 years, with a higher prevalence in males (73, 66.97%). Most patients (55, 50.46%) experienced their first flare between the ages of 7 and 12 years. A total of 45 patients (41.28%) had history of psoriasis vulgaris, 16 (14.68%) had history of acrodermatitis continua of Hallopeau, and 4 (3.67%) had history of psoriatic arthritis. Respiratory infection was the most common trigger, affecting 35 patients (32.11% of cases). The annual flare frequency was 0.68. The frequency and duration of flares showed a decreasing trend with increasing age. Earlier onset age is associated with a higher flare frequency. Before 2020, conventional therapies were most commonly used, with acitretin used in 67 patients (61.47%). Following 2020, secukinumab became the most often used medication (44 patients, 40.37%).
Conclusion:
PGPP exhibits a trend toward flare decrease with age, yet recurrence remains common. Earlier onset age may be associated with higher flare frequency. At present, biologic agents are the main treatment. These findings provide new insights into PGPP.
More Related Videos
Related Concept Videos
Pharmacokinetics in Pediatric Patients: Overview and Drug Absorption
COPD: Pathogenesis and Clinical Features
The primary cause for the onset of COPD is cigarette smoking and exposure to air pollution. These hazardous factors initiate a chain reaction within the lungs, resulting in chronic inflammation, damage to the airways, and a...
Pharmacokinetics in Pediatric Patients: Drug Excretion
Endocarditis II: Clinical Features of Infective Endocarditis
Pharmacokinetics in Pediatric Patients: Drug Metabolism
Pharmacokinetics in Pediatric Patients: Drug Distribution

